Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma

Blood

Volumn 119, Issue 13, 2012, Pages 3097-3104

  Nishikawa, Hiroyoshi ^a   Maeda, Yuka ^a   Ishida, Takashi ^b   Gnjatic, Sacha ^c   Sato, Eiichi ^d   Mori, Fumiko ^b   Sugiyama, Daisuke ^a   Ito, Asahi ^b   Fukumori, Yasuo ^e   Utsunomiya, Atae ^f   Inagaki, Hiroshi ^b   Old, Lloyd J ^c   Ueda, Ryuzo ^b   Sakaguchi, Shimon ^a,g  

^a OSAKA UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e OSAKA RED CROSS HOSPITAL   (Japan)

^f Imamura Bun in Hospital   (Japan)

^g KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CANCER TESTIS ANTIGEN; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; NY ESO 1 ANTIGEN; TUMOR ANTIGEN;

ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG TARGETING; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOMA; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LEUKEMIA;

EID: 84859328258     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-379982     Document Type: Article

References (50)

1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481-492. (Pubitemid 8180432)
2. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270-280. (Pubitemid 46480972)
3. Goncalves DU, Proietti FA, Ribas JG, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010;23(3):577-589.
4. Uchiyama T, Sagawa K, Takatsuki K, Uchino H. Effect of adult T-cell leukemia cells on pokeweed mitogen-induced normal B-cell differentiation. Clin Immunol Immunopathol. 1978;10(1):24-34. (Pubitemid 8326266)
5. Yagi H, Nomura T, Nakamura K, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol. 2004;16(11):1643-1656.
6. Matsubara Y, Hori T, Morita R, Sakaguchi S, Uchiyama T. Phenotypic and functional relationship between adult T-cell leukemia cells and regulatory T cells. Leukemia. 2005;19(3):482-483. (Pubitemid 40403338)
7. Chen S, Ishii N, Ine S, et al. Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. Int Immunol. 2006;18(2):269-277. (Pubitemid 43160140)
8. Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci. 2011;102(1):44-50.
9. Satou Y, Yasunaga J, Zhao T, et al. HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog. 2011;7(2):e1001274.
10. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458-5464. (Pubitemid 350232223)
11. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an International Consensus Meeting. J Clin Oncol. 2009;27(3):453-459.
12. Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116(8):1369-1376.
13. Takeda S, Maeda M, Morikawa S, et al. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer. 2004;109(4):559-567. (Pubitemid 38339647)
14. Suemori K, Fujiwara H, Ochi T, et al. HBZ is an immunogenic protein, but not a target antigen, for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes. J Gen Virol. 2009;90(8):1806-1811.
15. Verhasselt V, Milcent V, Cazareth J, et al. Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma. Nat Med. 2008;14(2):170-175. (Pubitemid 351214558)
16. Shimizu Y, Takamori A, Utsunomiya A, et al. Impaired Tax-specific T-cell responses with insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering stages. Cancer Sci. 2009;100(3):481-489.
17. Simpson AJ, Caballero OL, Jungbluth A, Chen Y-T, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615-625. (Pubitemid 41081387)
18. Caballero OL, Chen Y-T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100(11):2014-2021.
19. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1-30. (Pubitemid 44088423)
20. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83-117.
21. Xie X, Wacker HH, Huang S, et al. Differential expression of cancer testis genes in histological subtypes of non-Hodgkin's lymphomas. Clin Cancer Res. 2003;9(1):167-173. (Pubitemid 36109729)
22. Greiner J, Ringhoffer M, Taniguchi M, et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer. 2004;108(5):704-711. (Pubitemid 38076402)
23. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79(3):428-437.
24. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10):3625-3634. (Pubitemid 37169227)
25. Ri M, Iida S, Ishida T, et al. Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. Cancer Sci. 2009;100(2):341-348.
26. Stockert E, Jager E, Chen Y-T, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998;187(8):1349-1354. (Pubitemid 28189124)
27. Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli GC, Cerottini JC. Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int J Cancer. 2000;86(5):749-751. (Pubitemid 30249891)
28. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005;11(22):8055-8062. (Pubitemid 41698748)
29. Gnjatic S, Ritter E, Buchler MW, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad of Sci U S A. 2010;107(11):5088-5093.
30. Nishikawa H, Jager E, Ritter G, Old LJ, Gnjatic S. CD4+CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T-cell responses in cancer patients. Blood. 2005;106(3):1008-1011. (Pubitemid 41076447)
31. Nishikawa H, Sato E, Briones G, et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest. 2006;116(7):1946-1954. (Pubitemid 44033318)
32. Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol. 1999;29(10):3329-3337. (Pubitemid 29484224)
33. Barrow C, Browning J, MacGregor D, et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res. 2006;12(3):764-771. (Pubitemid 43259856)
34. Liu YN, Tian XL, Leitner WW, et al. Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo. J Biol Chem. 2011;286(43):37077-37084.
35. Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol. 2004;126(1):81-84. (Pubitemid 38859486)
36. Yano H, Ishida T, Inagaki A, et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer. 2007;120(9):2052-2057. (Pubitemid 46418388)
37. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127(4):759-767.
38. Toulza F, Nosaka K, Tanaka Y, et al. Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells. J Immunol. 2010;185(1):183-189.
39. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591-1598.
40. Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ regulatory T cells. J Exp Med. 2001;194(6):847-853. (Pubitemid 32983019)
41. Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res. 2004;10(22):7529-7539. (Pubitemid 39557514)
42. Ishida T, Joh T, Uike U, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study [published online ahead of print February 6, 2012]. J Clin Oncol. doi: 10.1200/JCO.2011.37.3472.
43. Harashima N, Kurihara K, Utsunomiya A, et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res. 2004;64(1):391-399. (Pubitemid 38114123)
44. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1. N Engl J Med. 2008;358(25):2698-2703. (Pubitemid 351860862)
45. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-924.
46. Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10(16):5494-5500. (Pubitemid 39100487)
47. Nakagawa M, Nakagawa-Oshiro A, Karnan S, et al. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/lymphoma. Clin Cancer Res. 2009;15(1):30-38.
48. Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402-3408.
49. Kannagi M, Harashima N, Kurihara K, et al. Tumor immunity against adult T-cell leukemia. Cancer Sci. 2005;96(5):249-255. (Pubitemid 40895071)
50. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570.